Off Patent
May 2027

Lyrica CR

pregabalin

Upjohn US 2 LLC

Tablet, extended release (oral) · NDA 209501

Last listed protection ends
May 2, 2027

The FDA lists 3 patents for Lyrica CR, and this is the day the last one ends. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Patent 8,945,620
    Claims the drug product and a use (U-2136, U-2137)
  2. Patent 9,144,559
    Claims the drug product
  3. Patent 10,022,447
    Claims a use (U-2136, U-2137)
  4. Patent 8,945,620
    Pediatric extension: six more months
  5. Patent 9,144,559
    Pediatric extension: six more months
  6. Patent 10,022,447
    Pediatric extension: six more months